Wednesday, July 8, 2026

Drug profile · INN

cysteamine hydrochloride

cysteamine hydrochloride (CYSTADROPS) is a cystine reducing agent. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — cysteamine hydrochloride
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
2
Data quality
0.84

Quick answer

cysteamine hydrochloride (CYSTADROPS) is a cystine reducing agent. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN cysteamine hydrochloride
Brand CYSTADROPS
Mechanism Cystine reducing agent
Target Cystine
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Cystine reducing agent

Primary target: Cystine

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. anti-CD19-CAR-T cells Phase 1 · Chongqing Precision Biotech · Systemic Lupus Erythematosus
  2. TEA plus GDMT Unknown · First People's Hospital · Heart Failure With Reduced Ejection Fraction

Related & competitor drugs

  1. cysteamine bitartrate Cystine reducing agent
  2. mercaptamine bitartrate Alimentary tract and metabolism (A16)

Frequently asked questions

What is cysteamine hydrochloride?

cysteamine hydrochloride (CYSTADROPS) is a cystine reducing agent. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for cysteamine hydrochloride?

CYSTADROPS is a marketed brand name for cysteamine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cysteamine hydrochloride?

cysteamine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.